Nutrition prescription to achieve positive outcomes in chronic kidney disease: A systematic review by Ash, Susan et al.
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Ash, Susan, Campbell, Katrina L., Bogard, Jessica, & Millichamp, Anna
(2014) Nutrition prescription to achieve positive outcomes in Chronic Kid-
ney Disease : a systematic review. Nutrients, 6(1), pp. 416-451.
This file was downloaded from: http://eprints.qut.edu.au/66678/
c© Copyright 2014 by the authors; licensee MDPI, Basel, Switzerland
This article is an open access article distributed under the terms
and conditions of the Creative Commons Attribution license
(http://creativecommons.org/Licenses/by/3.0/).
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
http://dx.doi.org/10.3390/nu6010416
 Nutrition Prescription to Achieve Positive Outcomes in Chronic 
Kidney Disease: A Systematic Review 
Susan Ash 1,*, Katrina L. Campbell 2, Jessica Bogard 3 and Anna Millichamp 3 
1 Institute of Health and Biomedical Innovation, School of Exercise and Nutrition Sciences, 
Queensland University of Technology, Brisbane, 4059, Australia 
2 Princess Alexandra Hospital, Brisbane 4001, Australia;  
E-Mail: Katrina_cambpell@health.qld.gov.au 
3 School of Exercise and Nutrition Sciences, Queensland University of Technology, Brisbane 4059, 
Australia; E-Mails: Jessica.bogard@live.com; a.spongberg@student.qut.edu.au 
* Author to whom correspondence should be addressed; E-Mail: s.ash@qut.edu.au;  
Tel.: +61-401-086-594; Fax: +61-731-383-690. 
Received: 27 October 2013; in revised form: 31 December 2013 / Accepted: 7 January 2013 /  
Published:  
 
Abstract: In Chronic Kidney Disease (CKD), management of diet is important in 
prevention of disease progression and symptom management, however evidence on 
nutrition prescription is limited. Recent international CKD guidelines and literature was 
reviewed to address the following question “What is the appropriate nutrition prescription 
to achieve positive outcomes in adult patients with chronic kidney disease?” Databases 
included in the search were Medline and CINAHL using EBSCOhost search engine, Embase 
and the Cochrane Database of Systematic Reviews published from 2000–2009. 
International guidelines pertaining to nutrition prescription in CKD were also reviewed 
from 2000–2013. Three hundred and eleven papers and eight guidelines were reviewed by 
three reviewers. Evidence was graded as per the National Health and Medical Research 
Council of Australia criteria. The evidence from thirty six papers was tabulated under the 
following headings: protein, weight loss, enteral support, vitamin D, sodium, fat, fibre, oral 
nutrition supplements, nutrition counselling, including protein and phosphate, nutrients in 
peritoneal dialysis solution and intradialytic parenteral nutrition, and was compared to 
international guidelines. While more evidence based studies are warranted, the customary 
nutrition prescription remains satisfactory with the exception of Vitamin D and phosphate. 
In these two areas, additional research is urgently needed given the potential of adverse 
outcomes for the CKD patient. 
Keywords: chronic kidney disease; dietetics; evidence based practice; diet therapy; 
nutrition prescription 
 
1. Introduction 
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Chronic kidney disease (CKD) is a prevalent chronic condition and the incidence of End-Stage 
Renal Disease (ESRD) is expected to continue to climb in the coming decade [1]. CKD has significant 
health and lifestyle implications for those affected, including increased risk of cardiovascular disease [2], 
malnutrition [3] and is a public health burden particularly in those patients who progress to end stage 
renal failure (or ESRD) and require kidney replacement therapy (dialysis) or transplantation [4]. The 
health cost burden is disproportionate to the prevalence with 5% of the health budget in the  
United States being consumed by 1% of the population requiring renal replacement [5]. CKD poses a 
significant public health issue and optimal treatment and management of this disease is indicated [6]. 
In CKD, nutrition and diet play an important role both in prevention of disease progression and in 
symptom management. The Dietitians Association Australia’s (DAA) Evidence based guidelines for 
the nutritional management of Chronic Kidney Disease (CKD) stages 1–5 [7] provide statements of 
evidence against clinical questions in line with the Nutrition Care Process (NCP) [8]. The guidelines 
are designed to be employed by dietitians in clinical practice as the basis of nutritional management of 
patients with CKD and are based on the nutrition component of several recognized international 
guidelines. The evidence used, dates from published guidelines to 2005, and some of these guidelines 
varied in the method of rating evidence. Since 2006, a number of new international guidelines have 
been published or revised using an agreed grading system [9] and together with new literature these 
need to be reflected in dietetic practice, specifically the nutrition intervention or prescription employed 
by clinical dietitians. This article reviews the evidence presented in recent international guidelines and 
literature that address the clinical question “What is the appropriate nutrition prescription to achieve 
positive outcomes in adult patients with chronic kidney disease?” 
2. Methods 
A systematic literature review of studies was designed to answer the clinical question. Databases 
included in the search were Medline and CINAHL using EBSCOhost search engine, Embase and the 
Cochrane Database of Systematic Reviews. MeSH terms for Medline and CINAHL were “kidney 
failure, chronic” AND “diet therapy” OR “nutrition intervention” and for Cochrane “kidney failure, 
chronic”. M-tree headings in EMBASE were “chronic kidney disease” AND “diet therapy” and further 
derivatives of diet therapy such as protein, phosphate. Results were limited to those published from 
2000–2009, papers reported in the English language and studies involving adult humans. Articles were 
excluded if they were not reported in full or if they were presented as tutorials, editorials, news, letters 
or comments. Articles were also excluded if they were included within any systematic reviews or  
meta-analyses retrieved. The research aims and outcome measures reported on were used to assess 
applicability of the studies. Reference lists of retrieved papers were also reviewed and studies included 
where relevant. Nutritional management of acute renal disease, transplantation and nephrotic 
syndrome were not included in this review. 
In addition to this systematic literature search, hand searches of recognised international guidelines 
published since 2006 and pertaining to nutrition were conducted. These included:  
• European Renal Association/European Dietitian and Transplant Nurses Association 
ERA/EDTNA European Best Practice Guideline on Nutrition, 2007 [10], 
 3 
 
• Guidelines for the management of chronic kidney disease by the Canadian Medical  
Association, 2008 [11],  
• Diagnosis and management of chronic kidney disease: A national clinical guideline by the 
Scottish Intercollegiate Guidelines Network, 2008 [12], 
• National Institute for Health and Clinical Excellence in the United Kingdom Chronic kidney 
disease: national clinical guideline for early identification and management in adults in primary 
and secondary care, 2008 [13], 
• Caring for Australians with Renal Impairment (also known as CARI guidelines), 2013 [14-16],  
• Kidney Disease: Improving Global Outcomes (KDIGO): Clinical practice guideline for the 
evaluation and management of Chronic Kidney Disease, 2012 [5,17],  
• American Dietetic Association Chronic Kidney Disease Evidence-Based Nutrition Practice 
Guideline, 2010 [18], 
• British Dietetic Association Evidence-based guidelines for the protein requirements of adults 
undergoing maintenance haemodialysis or peritoneal dialysis, 2013 [19]. 
Papers obtained through the literature search were categorized according to the aspect of nutrition 
prescription addressed in the research question, for example protein, phosphate, fat, vitamin D, oral 
nutrition support. The strength of evidence of these papers was then assessed by three independent 
reviewers and categorized according to recommendations from the National Health and Medical 
Research Council (NHMRC) evidence hierarchy [20]. The NHMRC grades the level of evidence  
from I, a systematic review of all relevant randomized controlled trials to IV evidence obtained from 
case series. An overall grading of evidence is provided by NHMRC whereby level of evidence, 
consistency across studies, clinical impact and generalisability is also assessed from A, where the body 
of evidence can be trusted to guide practice to D were the body of evidence is weak and 
recommendations should be applied with caution. This system has been recognized as equivalent to the 
Kidney Disease Improving Global Outcomes (KDIGO) criteria [21]. 
In a similar fashion, evidence statements from international guidelines were then grouped according 
to aspects of the nutrition prescription addressed with their corresponding levels of evidence. The 
grading systems and definitions for levels of evidence and strength of practice recommendations used 
by the various institutions guidelines are compared in Appendix 1. Statements from the recent guidelines 
were then listed against each of the nutrition parameters defined above. 
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3. Results 
Database searches using the search terms described above yielded 325 individual papers. Following 
grading of the evidence quality and exclusion of papers of lower level evidence, 34 papers remained 
for inclusion in this review. Of these, five papers were systematic reviews, fourteen were randomized 
controlled trials, nine were prospective cohort or comparative studies with controls and six were 
interrupted time series or case series. Table 1 compares the systematic reviews of protein intake both 
in those with and without diabetes, weight management and enteral support on renal outcomes. Table 2 
compares the evidence for the remaining studies according to nutrient parameters, such as protein, 
vitamin D, fats, sodium, fibre; or intervention, such as oral nutrition support, dietetic counseling, 
including phosphate, nutrients in peritoneal solution, intradialytic parenteral nutrition or percutaneous 
endoscopic gastrostomy feeding. Table 3 outlines statements from international guidelines against each 
of these parameters. 
In Table 1, the systematic reviews of protein intake [22-24] indicate that in pre-dialysis, protein 
should be reduced to 0.6 g/kg body weight/day or equivalent if using keto-analogues and diet combined. 
Reduction to this level resulted in a 32% reduction in renal deaths (RR 0.68, 95% CI 0.55 to 0.8,  
p = 0.0002). For those with diabetes, both Types 1 and 2, reducing protein is associated with moderate 
non-significant slowing in progression of diabetic nephropathy resulting in renal failure [24].  
Protein intakes <0.8 g/kg body weight/day showed no compromise in anthropometry or biochemical 
indicators [23]. One systematic review was retrieved that examined weight loss interventions in  
CKD [25]. This review analysed 13 studies, two RCTs and 11 observational studies and found that 
only modest evidence exists to support the role of intentional weight loss on slowing CKD progression 
in mild-moderate CKD. A systematic review of enteral feeding in maintenance HD included 5 RCT 
and 13 non-RCT and concluded that enteral feeding, including oral nutrition support vs. routine care 
increased protein and energy intake and improved serum albumin by 0.23 g/dL but there was 
insufficient data to examine the effect on clinical outcomes [26]. 
Table 2 outlines individual papers. There is evidence that for those patients with ESRD either  
Stage 4 or 5, a very low protein diet (0.3 g/kg/day) with added keto-analogues and adequate energy  
(35 kcal/day) can delay dialysis with no adverse effect on mortality [27]. Elderly patients with 
glomerular filtration rate (GFR) between 5–7 mL/min on a similar diet, when compared to those on 
dialysis, had better outcomes with an improved survival of 3.6% (95% CI, −17 to +10; p = 0.002) [28]. 
In dialysis, protein intakes of >1.2 g/kg/day resulted in significant increases in body mass index (BMI, 
kg/m2) of 0.97 (p < 0.001) [29]. The association between protein intake and all-cause mortality and 
cardiovascular mortality amongst a large retrospective cohort, found that survival was best at protein 
intakes between 1.0–1.4 g/kg/day and that intakes <0.8 g/kg/day and >1.4 g/kg/day were associated 
with increased mortality. However, this effect was diminished significantly when adjusted for 
malnutrition inflammation complex syndrome [30]. 
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Table 1. Systematic reviews of nutrition interventions in patients with chronic kidney disease (CKD. 
Author Number of Studies Sample Outcome Measures Results Conclusions 
Level of 
Evidence [20] 
Protein (patients without diabetes) 
Fouque  
[22] 
10 RCT *s 
n = 2000 Pre-dialysis, 
Stages 3–5 
Renal death (death of any cause, 
requirement to start dialysis or 
kidney transplant) 
RCTs or cross-over studies (if start date 
allocated randomly). Protein intake 
 (≥0.8 g/kg/day) vs. moderate (0.6 g/kg/day) to 
severe protein restriction (0.3 g/kg/day) 
regardless of supplementation with amino 
acids or keto-acids. Participants with moderate 
to severe CKD * (as per GFR *, serum 
creatinine or creatinine clearance). 
A nutritional intervention that includes a reduction in 
protein intake should be proposed to patients with 
moderate CRF *. Reducing protein intake overall 
reduced renal deaths by about 32% (p = 0.0002). 
Sub-analysis (7 studies) found that reduced protein 
intakes between 0.3 and 0.6 g/kg/day compared to 
higher/free protein intakes resulted in a significant 
reduction in renal deaths (37%, p = 0.0009).The 
optimal level of protein intake cannot be determined 
based on this review. 
I 
Zarazaga 
[23] 
26 studies, Including 
3 meta-analyses 
N.B. 3 studies 
included paediatric 
patients 
N = 7155 Dialysis + 
Pre-dialysis (Stages 
not defined) 
Compliance with diet Mortality, 
GFR, renal function 
Anthropometry Biochemistry 
(various factors that address 
overall renal function) 
Nutritional status 
Patients aged 2–65 years with chronic renal 
failure in dialysis or pre-dialysis. Interventions 
of nutritional support with amino acid or  
keto-acid supplements with or without 
restriction of protein intake. Protein  
restricted to equivalent of 0.6 g/kg/day,  
energy 30–40 kcal/day and  
phosphate 700–800 mg/day in interventions. 
Dietary protein should be restricted to 0.4–0.6 g/kg/day. 
A protein intake of 0.6 g/kg/day (comprising  
0.4 g/kg/day + 0.2 g/kg/day from supplements) 
improves the course of renal function, nutritional status 
and lipid profile, with good compliance. VLPD * and 
LPD * (using specific enteral supplements) should be 
used by most patients in the early stages of CRF * to 
slow progression of renal failure. For patients with CRF 
on dialysis, prescription of a VLPD does not reduce 
frequency of dialysis sessions. 
I 
Protein (patients with diabetes) 
Robertson 
[24] 
12 studies (9 RCTs 
and 3 before and 
after studies) 
n = 585  
(T1DM = 322,  
T2DM = 263) 
Compliance with low protein 
diet Biochemistry (GFR)  
All- cause mortality, ESRD * 
Nutritional status, Health related 
QOL *, Costs 
RCTs or before and after studies. Interventions 
of reduced or modified protein intake ≥4 months. 
Participants of any age with type 1 or 2 DM *, 
with nephropathy (UAER * ≥ 300mg/day). 
Reducing protein intake is associated with a moderate, 
non significant slowing in the progression of diabetic 
nephropathy to renal failure. A specific recommendation 
of the necessary protein level to achieve this outcome 
is not possible. 
I 
*LPD Low protein diet; *CRF Chronic Renal Failure, * GFR Glomerular Filtration Rate; * RCT Randomised Controlled Trial; * VLPD Very low protein diet; *QOL Quality of Life; *DM Diabetes Mellitus; *CKD Chronic Kidney 
Disease; *UAER Urinary Albumin Excretion Rate; BMI Body Mass Index; *BP Blood Pressure; * HbA1C  Glycosylated Haemoglobin; *HD Haemodialysis. 
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Table 1. Cont. 
Zarazaga  
[23] 
19 studies Including 
1 systematic review 
N = 280 Diabetic 
nephropathy  
(Stages not defined) 
GFR, proteinuria, renal 
function, anthropometry/ 
nutritional status, compliance 
with diet, hyperglycemia, 
insulin requirements 
Patients with insulin dependent diabetes. 
Interventions of nutritional support with amino 
acid or keto-acid supplements with or without 
restriction of protein intake 
Protein restricted diets at least <0.8–1 g/kg/day is only 
recommended in Type 1 DM, showing reduction in 
hyperglycemia and decreased insulin requirements. 
Anthropometric parameters were preserved. LPD 
(using specific enteral supplements) should be used 
by patients in the early stages of diabetic nephropathy 
to slow progression of renal failure. No specific 
protein intake levels are prescribed. 
I 
Weight loss (patients with and without diabetes)  
Navaneethan 
[25] 
13 studies (2 RCT 
and 11 observational) 
n = 520  
(174 non-surgical 
interventions,  
346 surgical 
interventions)  
Stages 1–4 
Renal function (GFR or 
creatinine clearance, 
proteinuria). Anthropometry 
(BMI *). Biochemistry 
(HbA1C *, serum lipids). 
Other (Blood Pressure) 
Obese patients (BMI ≥ 30). RCTs or 
observational studies of surgical or non-surgical 
weight loss interventions among patients with 
either existing CKD or obesity-related glomerular 
hyperfiltration. Follow up of ≥4 weeks. 
Non-surgical weight loss did not elicit change in GFR 
or creatinine clearance, but was associated with a 
reduction in proteinuria, BMI, Systolic BP * and 
Total cholesterol. Surgical weight loss was associated 
with normalisation of GFR in glomerular 
hyperfiltration, significant reduction in BMI, 
proteinuria and systolic BP. Only modest evidence to 
support the role of intentional weight loss in slowing 
CKD progression in mild-moderate CKD 
I 
Enteral support 
Stratton [26] 
18 studies 
(5 RCT and  
13 non-RCT) 
Maintenance HD *, 
Stage 5 
Clinical: QoL*, Complications, 
mortality Biochemical: 
albumin and electrolyte levels 
Nutritional: dietary intake, 
anthropometry 
Multi-nutrient oral supplements and enteral 
tube feeding which included nutrition support 
(NS) with routine care; disease specific 
formula with standard formulae; enteral 
feeding with parenteral feeding. 
Enteral feeding vs. routine care increased energy and 
protein intake and increased serum albumin 
concentration by0.23 g/dL (2.3 g/L: 95% CI * 0.037 
to 0.418 g/dL. There was insufficient data to examine 
the effect of this on clinical outcomes. Additional 
research required, especially comparing disease 
specific formulae with standard formulae. 
I 
*LPD Low protein diet; *CRF Chronic Renal Failure, * GFR Glomerular Filtration Rate; * RCT Randomised Controlled Trial; * VLPD Very low protein diet; *QOL Quality of Life; *DM Diabetes Mellitus; *CKD Chronic Kidney 
Disease; *UAER Urinary Albumin Excretion Rate; BMI Body Mass Index; *BP Blood Pressure; * HbA1C  Glycosylated Haemoglobin; *HD Haemodialysis. 
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Table 2. Experimental and observational studies addressing various aspects of the nutrition prescription in CKD. 
Author 
Study Design 
and Length 
Sample 
Characteristics 
Intervention Outcomes Results/Conclusions 
Level of 
Evidence 
[20] 
Protein—experimental studies 
Feiten [31] 
RCT*   
(4 months) 
n = 24 Pre-dialysis 
(Stage 4 and 5) 
>18 years 
Intervention: VLPD *  
(0.3 g vegetal protein/kg IBW 
*/day) + KA * Control: LPD   
(0.6 g protein/kg IBW/day) 
Nutrient intake & compliance  
(3 day food diary, normalised 
protein appearance (nNPA* )). 
Anthropometry (BMI*, 
%TSF *,%MAMC *, LBMI *). 
Serum and urinary urea, serum 
creatinine, ionised calcium, 
bicarbonate, albumin, iPTH , 
eGFR*) 
Nutritional status was maintained but compliance was poor in both 
groups. Protein intake was underestimated by approximately 28% in 
both groups when food records and nNPA were compared. Actual 
protein intake of intervention group decreased significantly from  
0.9 ± 0.24 g/kg/day to 0.66 ± 0.11 g/kg/day at 4 months (p < 0.05) 
while energy remained stable (22.9 kcal/kg/day in VLPD* and  
24 kcal/kg/day in LPD. Serum urea nitrogen from 61.4 to  
43.6 mg/dL, p < 0.001. Dietary PO4 * decreased, with 
improvements in  
Ca * and PTH * metabolism. 
II 
Cianciaruso [32] 
Follow up data 
from a RCT  
(48 months) 
n = 423  
Pre-dialysis  
(stage 4 and 5) 
Intervention: LPD*  
(0.55 g/kg/dat) Control: MPD * 
(0.8 g/kg/day) 
Protein energy malnutrition; 
Progression to dialysis; Mortality; 
Composite end point (death or 
dialysis) 
Protein intakes were 0.73 ± 0.04 g/kg/day for LPD and 0.9 ± 0.06 
g/kg/day for MPD. Unadjusted Cox survival analyses were 1.01 
(95% CI*  0.57–1.79) 0.90 (95% CI 0.62–1.48) and 0.98 (95% CI 
0.68–1.43) respectively for death, progression to dialysis or 
composite end point with no differences in outcome of either 
intervention. 
II 
Brunori [28] RCT (1 year) 
n = 112 (Stage 5 
GFR 5–7 mL/min) 
Intervention: LPD  
(0.3 g/kg/day, 35 kcals/day + 
ketoacids, vitamins, minerals. 
Control: Dialysis 
Mortality, hospitalization, 
metabolic markers 
Median follow-up was 26.5 months (IQR*, 40). Patients in diet 
group spent median 10.7 months on VLPD (IQR*, 11). 31 deaths 
(55%) in the dialysis group; 28 deaths (50%) in the diet group. 
One-year observed survival rates at intention to treat 83.7%  
(95% CI, 74.5 to 94.0) dialysis group versus 87.3% (95% CI, 78.9 
to 96.5) diet group; difference in survival −3.6% (95% CI, −17 to 
−10; p = 0.002). The hazard ratio for hospitalization was 1.50 for 
the dialysis group (95% CI, 1.11 to 2.01; p <0.01). 
II 
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Table 2. Cont. 
Protein—observational studies 
Vendrely [29] 
Comparative 
study with  
con-current 
controls,  
12 months 
n = 30 Dialysis 
(Stage 5, HD *) 
Intervention group: VLPD  
(0.3 g/kg/day supplemented with 
essential amino acids, Calcium, 
Iron and vitamins) prior to 
initiation of HD. Control: Less 
restrictive diet (~0.9 g/kg/day) 
prior to initiation of HD. 
Nutrient intake (3 day food 
record  
every 3 months). Anthropometry 
(BMI, body composition by 
DEXA). Serum albumin and  
pre-albumin. 
Protein intake ↑ to >1.2g/kg/day, BMI ↑ by 0.97 ± 1.31 kg/m2,  
p < 0.001, due to ↑ in fat mass 2.36 ± 2.94 kg/m2, p < 0.001  
in both groups 3 months after commencement of HD. No differences 
were observed between groups for LBM, BMI,  
serum albumin or pre-albumin. 
III-2 
Kanazawa [33] 
Comparative 
study with 
concurrent 
controls (not 
randomised) 
n = 65  
Pre-dialysis 
(Stages 3–5) 
Case group:  
Non-compliant on LPD  
(0.69 g/kg/day) > 3 months. 
Control group: Compliant on LPD 
(0.69 g/kg/day) > 3 months  
Biochemistry (GFR, serum 
creatinine, BUN *, reciprocal of 
serum creatinine). Dietary 
compliance (3 day food records, 
PCR *). Health related QOL * 
Change in mean GFR rate was lower in compliant group  
(−0.063 ± 1.306 compared to −0.742 ± 1.18, p < 0.05. No difference 
between groups for health-related QOL. 
III-2 
Shinaberger [30] 
Retrospective 
cohort  
study. 2 years 
n = 53,933 
Dialysis (Stage 5, 
Maintenance HD) 
Historical review of maintenance 
HD patients’ protein intake 
(measured by nPNA and 
categorised into 10 increments) & 
mortality 
Protein intake ( measured by 
nPNA) MICS * (malnutrition-
inflammation complex 
syndrome) All-cause mortality 
Cardiovascular mortality 
Hazard ratios were not significantly increased with nPNA between 1–
1.4 g/kg/day but increased to 1.34 (95% CI 1.23–1.46, p < 0.0001), 
when levels were <0.6 or ≥1.4 g/kg/day. Protein intakes of <0.8 or  
>1.4 g/kg/day associated with greater mortality, even when adjusted 
for MICS and case mix. Increasing protein intake of patients in  
the 0.8–1.2 g/kg/day protein range within the first 6 months, tended to 
reduce mortality risk, whilst a decreased protein intake in the first 6 
months, increased the risk. 
III-3 
Chauveau [27] 
Prospective 
cohort study no 
concurrent 
controls, 5 years 
n = 203 Predialysis 
(Stage 4–5) 
VLPD (0.3 g protein/kg/day,  
35 kcal/day,  
5–7 mg phosphate + ketoacids) 
for >3 months 
Mortality; Progression to dialysis  
or transplant 
Mean duration of diet period 33.1 months (4–230). Overall survival 
rate 79% and 63% at 5 and 10 year, respectively. 102 patients continued 
with chronic dialysis during the entire follow-up, and  
101 patients were grafted at least once. No correlation between death 
and duration of diet. 
III-3 
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Table 2. Cont. 
Vitamin D—experimental studies 
Fishbane [34] 
RCT (double 
blind, 6 months 
n = 61 Pre-dialysis 
(Stages 1–4).  
Intervention: oral paricalcitol,  
1 μg/day Control: placebo 
Biochemistry (mean spot urinary  
protein-creatinine ratio, serum intact 
PTH, serum calcium, serum phosphorus, 
urine creatinine) 
Significant decrease in proteinuria in paricalcitol group. Mean spot 
urinary protein-creatinine ratios were +2.9% in controls and −17.6% 
in the intervention group (p = 0.04). Serum iPTH ↓significantly in 
intervention group (p = 0.01). 57.6% of paricalcitol group had a 
more than 10% decline in proteinuria. Modest effect size noted as is 
small study size. 
II 
Agarwal [35] 
RCT (double 
blind, 24 weeks 
n = 220  
Pre-dialysis  
(Stage 3–4) 
Secondary 
hyperparathyroidis
m 
Intervention: oral paricalcitol 
9.5 μg/week Control: placebo 
Proteinuria 
51% intervention group cf 25% control reduced proteinuria (OR 
3.2, 95% CI 1.5–6.9, p = 0.004). For those with proteinuria and 
PTH suppression (2 consecutive ≥30% decrease in iPTH from 
baseline) proteinuria decreased 53% intervention vs. 0% in control. 
II 
Vitamin D—observational studies 
Wang [36] 
Cohort study 
(prospective),  
3 years 
N = 230 Dialysis 
(Stage 5, PD *) 
Serum Vitamin D (25(OH)D) 
and clinical outcomes  
(death, fatal cardiovascular 
event, non-fatal 
cardiovascular event) 
Anthropometry (BMI) Serum 25(OH)D, 
eGFR echocardiography Nutritional 
status (SGA *) Dialysis adequacy  
All cause mortality Cardiovascular 
events (fatal or non-fatal) 
87% of cohort were deficient or insufficient in 25(OH)D  
(<75 nmol/L). Kaplan Meier estimates show a significantly greater 
fatal or non-fatal CV * event-free survival probability in patients 
whose 25(OH)D >median 45.7 nmol/L than those with median  
≤45 nmol/L (p = 0.004). 
III-2 
Fats—experimental studies 
Beavers [37] 
RCT (double 
blind, permuted-
randomised), 6 
months 
n = 69 Dialysis 
(Stage 5, HD) 
Intervention: daily 
supplement of 6 g n-3 fatty 
acids in the form of fish oil 
(160 mg EPA *, 100 mg 
DHA *) Control:6 g daily 
supplement corn oil (n-6) 
Biochemistry (total homocysteine) 
Compliance: Pill counting (NB did not 
use in vivo testing) 
 Over the counter omega-3 fatty acids at 6 g per day have no effect 
on total homocysteine compared to a placebo. 
II 
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Table 2. Cont. 
Fats—observational studies 
 Saltissi [38] Case series, 14 weeks 
n = 75  Dialysis 
(Stage 5, HD and 
PD) with 
dyslipidaemia 
Dietary prescription: 
Adjustment of “dialysis diet” 
to bring in line with 
Australian NHF * guidelines 
to reduce lipid levels for 
chronic PD and HD patients 
Anthropometry (BMI). Nutrient 
intake: Dietary assessment and 
computer analysis,  
Biochemistry (total, HDL * , LDL *, 
VLDL * cholesterol, TG *) 
In HD patients, decreased saturated fat and cholesterol intake was 
associated with a decrease in total cholesterol (p = 0.007) and 
LDL cholesterol (p < 0.01) but not in PD. Most dialysis patients  
will require pharmacologic lipid lowering treatment for  
adequate control. 
IV 
Sodium and fluid—experimental studies 
Vogt [39] 
RCT (double blind, 
placebo controlled 
crossover), 36 weeks 
Patients with 
proteinuria (various 
diagnoses) 
Intervention: Treatment  
with placebo, Losartan, 
Losartan + HCT * whilst 
randomised to either high 
sodium (200 mmol/day) vs. 
low sodium (50 mmol/day) 
diet. 
Anthropometry (BMI). Biochemistry 
(proteinuria, serum creatinine, urea, 
cholesterol, triglycerides, total protein 
and albumin). Other (urinary sodium 
excretion, mean arterial pressure, 
systolic and diastolic blood pressures) 
Baseline proteinuria was decreased by 22% by LSD * alone, 
Losartan decreased proteinuria by 30%, Losartan  + LSD 
decreased proteinuria by 55%. The combined addition of HCT 
and low-sodium diet decreased proteinuria by 70% from baseline 
(all p < 0.05). Reductions in mean arterial pressure showed a 
similar pattern (all p< 0.05). A low sodium diet and HCT are 
equally efficacious in reducing proteinuria and BP when added to 
a regimen containing Losartan and especially seem to benefit 
individuals in whom proteinuria is resistant to  
Renin-Angiotensin-Aldosterone system blockade. Sodium 
restriction exerted a modest but significant antiproteinuric effect. 
II 
Sodium and fluid—observational studies 
Kayikcioglu 
[40] 
Retrospective cross 
sectional study 
comparing 2 centres,  
I year 
n = 394 Stage 5, 
HD. Centre A (n = 
190)–salt 
restriction. Centre 
B  
(n = 204)–
hypertensive drugs 
Intervention: salt restricted 
diet (5g/day) and intensive 
ultrafiltration to maintain  
pre-dialysis B, P < 140/90 
mmHg without 
antihypertensive medication. 
Control: Hypertensive drugs 
Hypertensive drug use.  
Weight and BP. Systolic  
and diastolic function. Intradialytic 
hypotension 
Antihypertensive drugs used in 7% Centre A and 42% in Centre 
B (p < 0.01); Interdialytic weight gain was significantly lower in 
Centre A (2.29 ± 0.83 kg vs. 3.31 ± 1.12 kg, p < 0.001). Mean 
systolic and diastolic BP similar. Frequency of LV hypertrophy 
was lower in Centre A (74% versus 88%, p < 0.001). 
Intradialytic hypotension (hypotensive episodes/100 patient 
sessions) was more frequent in Centre B (11 versus 27, p < 
0.01). 
III-2 
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Boudville 
[41] 
Retrospective cohort,  
5 years 
n = 141. (Stages 4–
5, including dialysis 
+ 24 h urine 
collection  
for sodium) 
24 h sodium excretion divided 
into tertiles. Percentiles 33.3 and 
66.6 being 114.0 mmol/day Na. 
(2.7 g/day) and 166.7 mmol/day 
Na (4.0 g/day), respectively 
Hypertensive drug use.  
BP control 
Mean (±SE) sodium excretion 145.7 ± 4.7 mmol/day (3.5 g 
Na/day). Control of BP equivalent in all groups. Greater no. 
antihypertensive agents with increased sodium excretion (2.00 ± 
0.16, 2.61 ± 0.20, and  
2.77 ± 0.19 medications, respectively for each tertile; p = 0.01). 
For those with GFR ≤ 15 mL/min (n = 77) medications used 
with increased sodium excretion  1.69 ± 0.19, 2.52 ± 0.27, and 
3.08 ± 0.26, respectively; p = 0.001. Multivariable analysis 
sodium excretion  
(p = 0.00005) and age (p = 0.007) significantly associated with 
use of antihypertensive medication. 
III-3 
Fibre—experimental studies 
Sutton [42] 
Interrupted time  
series without parallel 
control group 
Stage 1: n = 126  
Stage 2 4 weeks: n = 
23 Stage 3 3 weeks: 
n = 17 Dialysis 
(Stage 5, PD) 
regularly using 
laxatives  
Stage 1: Survey Stage 2: 
laxative users replaced laxatives 
with 6–12 g/day partially 
hydrolysed guar gum supplement 
Stage 3: dietary counselling to 
support increased dietary fibre 
intake of 6–12 g/day from foods 
Patient reported preference for 
efficacy, ease of administration, 
acceptability of taste and texture for 
laxative, supplement or increased 
dietary fibre.Self reported bowel 
habits (Bristol stool chart) Laxative 
use 
Of 23 patients involved in intervention, 15 thought the fibre 
supplement provided best stool result and reduced side effects 
and 14 preferred the supplement over laxative. No objective 
data reported. Poor quality study, as reported outcomes were 
not matched objectively against fibre intake. 
IV 
Oral nutrition supplements—experimental studies 
Teixido-
Planas [43] 
Open RCT (multicentre), 
12 months 
n = 65. Dialysis  
(Stage 5, PD) 
Intervention: 200 mL  
(1.0 kcal/mL) liquid protein 
supplement daily in addition to 
normal dietary intake. Control: 
no protein supplement, usual  
dietary intake 
Nutrient intake (3 day food record). 
Anthropometry (BMI , skinfolds, BSA 
*). Nutritional status (SGA). 
Biochemistry (full blood count, serum 
albumin, lymphocyte count, lipids, 
urea, creatinine). Clinical (dialysis 
adequacy, urinary and peritoneal 
losses). Patient compliance (patient 
report, family report, inventory check). 
Intention to treat analysis revealed a significant improvement in 
the intervention group in lymphocyte count (p < 0.001), 
weight (p < 0.03), TSF (p < 0.001), MAMC * (p < 0.005). 
The supplement used was not suitable for long term use due 
to a high rate of non-compliance and high dropout in the 
intervention. Malnutrition assessed by SGA  decreased from 
29% in intervention to 0% and from 33% in controls to 20%. 
II 
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Caglar [44] 
Pilot prospective 
cohort study, 9 months, 
with 3 months baseline 
n = 85. Dialysis  
(Stage 5,  
HD + diagnosed 
malnutrition) 
Intervention: 200 mL  
(2.0 kcal/mL) liquid protein 
supplement during dialysis 
treatment, 3 to 9 months 
Control: standard nutritional 
counselling, baseline to 3 
months 
Nutrient intake (48 h dietary recall). 
Anthropometry (BMI). Biochemistry 
(albumin, pre-albumin, transferrin). 
Nutritional status (SGA) 
ONS * improved nutritional parameters (significant increase 
in serum albumin (3.33 ± 0.32 g/dL baseline to 3.65 ± 0.26 g/dL 
end 6 month intervention, p < 0.0001), serum pre-albumin 
(26.1 ± 8.57 g/dL baseline to 30.7 ± 7.36 g/dL end 6 month 
intervention, p < 0.0001) and SGA score (4.94 ± 1.23 g/dL 
baseline to 5.64 ± 0.90 g/dL end 6 month intervention,  
p < 0.05)). BMI and body weight increased non-significantly 
from baseline to end of intervention. Note: High  
non-compliance rate (32%). Less than half of participants 
completed the study (46%). 
III-2 
Oral nutrition supplements—experimental studies 
Gonzales-
Espinoza 
[45] 
Open RCT, 6 months 
n = 28. Dialysis  
(Stage 5, PD) 
Intervention: nutritional 
counselling + 30 g oral  
egg-albumin protein supplement 
of 22 g protein/day. Control: 
nutritional counselling. 
Nutrient intake (24 h recall). 
ometry (BMI, skin folds). 
Biochemistry (serum albumin, 
e, lipids, nPNA, glucose, BUN *). 
 ialysis adequacy). 
Patient compliance (weighed 
y of supplement). 
Frequency of moderate-severe malnutrition decreased 28% in 
intervention group (vs. 6% in control group). Comparing 
baseline to  
6 months, ONS significantly improved serum albumin (2.64 ± 
0.35 vs. 3.05 ± 0.72 g/dL) and energy intake (1331 ± 342 vs.  
1872 ± 698 kcal/day) in the same group, p < 0.05 and protein 
intake (1.0 ± 0.3 vs. 1.7 ± 0.7 g/kg) and nPNA (1.00 ± 0.23 vs.  
1.18 ± 0.35 g/kg/day) within and between groups (p < 0.05) 
with a trend to increased anthropometric parameters and 
nutritional status in the intervention group. Multivariate 
analysis showed only serum albumin significantly predicted 
by ONS (β 0.72, 95% CI 0.14–1.3, p = 0.02) and % protein 
intake (β −0.01, 95% CI0-  −0.02, p = 0.05) and SGA 
significantly predicted by TSF (RR 0.79, 95%CI  
0.63 −0.98, p = 0.03. Compliance was high at 90%.  
II 
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Nutritional Counselling—intervention studies 
Campbell 
(2008) [46] 
RCT (12 weeks) 
n = 56. Pre-dialysis  
(Stage 4 and 5) 
Intervention: Regular and 
individualised dietary 
counselling. Control: written 
nutrition education material  
Nutrient intake (3 day food 
record). Anthropometry (body 
composition). Nutritional status 
(SGA) 
Intervention group had a 3.5% (95% CI −2.1 to 9.1), less 
decrease in body cell mass, 17.7 kJ/kg/day (95% CI 8.2 
to 27.2) increase in energy intake, greater improvement 
in SGA, all p < 0.01 and no significant increase in 
protein intake. Structured nutrition intervention had a 
greater effect on energy and protein intake in women 
than men (interaction p < 0.001 for both). 
II 
Campbell 
(2008) [47] 
RCT (12 weeks) 
n = 53. Pre-dialysis  
(Stage 4 and 5) 
Intervention: Regular and 
individualised dietary 
counselling. Control: written 
nutrition education material  
Nutritional status (PG-SGA *). 
KDQoL * 
Intervention showed significant improvement in subscales of 
KDQoL compared to nutritional status: symptoms 7.1 (0.1–
14.1),  p = 0.047; cognitive functioning 14.6 (5.4–23.7), p = 
0.03; vitality 12.0 (4.6–19.5) p = 0.002. 
II 
Nutritional Counselling—intervention studies 
Sullivan, 
Sayre et al. 
2009 [48] 
Cluster RCT,  
14 facilities, 2 shifts at 
12 large centres  
and 1 shift at 2 small 
centres, 3 months 
n = 279. HD (Stage 5). 
Intervention n = 145: 
Control n = 134 
Intervention: education on avoiding 
food with PO4 * additives. Control: 
Usual care. 3 month duration 
Change in serum PO4 
Intervention gp showed decrease in serum PO4 of −0.6mg/dL 
(95% CI −1.0 to −0.1mg/dL, p = 0.03). This change was not 
explained by change in food knowledge score but intervention 
group showed significant improvements in reading nutrition 
facts label score 9 (95% CI 1 to 17, p = 0.04) and food 
ingredients list score 22 (95% CI 15–30 p < 0.001). 
II 
Morey, 
Walker  
et al. [49] 
RCT, 6 months 
n = 67 stable HD 
(Stage 5) 
Intervention: Monthly dietetic 
counselling to improve PO4  
intake and binder adherence.  
Control: 6 month counselling 
Change in serum PO4,controlling 
for serum PO4, binder use and 
alphacalcidrol at baseline 
Intervention gp showed decrease in serum PO4 at 3 mths 
approaching significance when controlled for confounders –
0.253 mg/dL (95% CI −0.513 to 0.007 mg/dL, p = 0.056) 
compared to control however this difference disappeared at 6 
months. 
II 
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Nutritional Counselling—observational studies 
 Campbell 
(2009)  [50] 
Retrospective 
observational study,  
2 years with 3 time 
points 
n = 65. Dialysis (Stage 5, 
maintenance HD) 
Dietary interview (at least  
every 6 months with intensive 
follow up where required). 
Nutrient intake (dietary interview). 
Anthropometry (serum albumin and 
potassium). Biochemistry. Nutritional 
status (SGA) 
Proportion of patients with malnutrition (as per 
SGA) decreased from 14% to 3% after 2 years. 
Serum albumin, potassium and dry weight 
remained stable. Significant decrease in serum 
phosphate (mean ± SD, 1.8 ± 0.5 to 1.5 ± 0.5 
mmol/L, p = 0.004). Energy intake increased to 
105 kJ/kg from 102 kJ/kg at baseline (p = 0.001) 
and protein intake increased from 1.14 g/kg/day to 
1.18g/kg/day (p = 0.022).  
Under-reporting occurred in 30%–60% patients. 
III-3 
Nutrients in peritoneal dialysis solution—experimental studies 
Tjong 
(2005) [51] 
Randomised  
cross-over study,  
14 days 
n = 8. Dialysis  
(Stage 5, PD) 
Intervention: AAPD *  
(plus glucose). Control: Standard 
PD solution 
Biochemistry (WBPT *, 24 h nitrogen 
balance) 
Net protein balance (protein 
synthesis minus protein 
breakdown) increased on AA 
PD in all patients (mean 0.21 
± 0.12 μmol leucine/kg per 
min; p < 0.001). The 24-h 
nitrogen balance changed by 
0.96 ± 1.21g/day, from −0.60 
± 2.38 to 0.35 ± 3.25 g/day (p 
= 0.061, NS), improving in 
six patients. 
II 
Nutrients in peritoneal dialysis solution—observational studies 
Sezer 
(2006) [52] 
Prospective, open 
labelled uncontrolled 
study , 3 months 
n = 16. Dialysis  
(Stage 5, PD) with 
hypoalbuminaemia 
Amino acid peritoneal dialysis 
(AAPD). 1 dextrose peritoneal 
dialysate exchange/day replaced 
by a 2L AAPD bag. 
Anthropometry (LBM *). Biochemistry 
(albumin, lipids). Nutritional status 
(SGA) 
Albumin improved 3.5 ± 0.5 g/dL to 4.1 ± 0.4 g/dL (p = 
0.003); HDL cholesterol level decreased from 43.1 ± 7.3 
mg/dL to 37.8 ± 6.0 mg/dL (p = 0.02), even though other 
lipid parameters (total cholesterol, triglyceride and LDL 
cholesterol) did not change. 
IV 
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Intradialytic Parenteral Nutrition—experimental studies 
Pupim 
(2004) [53] 
Randomised 
prospective cross over 
study 
n = 7. Dialysis  
(Stage 5, HD) 
IDPN * 
Biochemistry (albumin fractional 
synthetic rate, WBPT *) 
Nutritional supplementation in the form of IDPN improves th  
hepatic synthesis of albumin (16.2 ± 1.5%/day vs.12.8 ± 
1.7%/day, p < 0.05) as a part of improvements in the whole b  
protein synthesis (5.05 ± 0.3mg/kg fat-free mass/min vs. 3.22  
0.3 mg/kg fat-free mass/min (p < 0.05). 
II 
Pupim 
(2006) [54] 
Randomised 
prospective cross over 
study 
n = 8. Dialysis  
(Stage 5, HD) 
Intervention: IDPN or oral 
nutritional supplement during 
HD treatment. Control: normal 
HD treatment 
Biochemistry (albumin, prealbumin, 
transferrin, metabolic hormones, serum 
protein, etc.) 
Positive whole-body net balance during HD with both IDPN 
and ONS, 4.43 ± 0.7 and 5.71 ± 1.2 mg/kg fat-free mass per 
min, respectively, compared with control (0.25 ± 0.5 mg/kg 
fat-free mass per min; p = 0.002 and <0.001) for IDPN versus 
control and ONS versus control, respectively. ONS resulted in 
persistent anabolic benefits in the post-HD phase for muscle 
protein metabolism, when anabolic benefits of IDPN 
dissipated. 
II 
Intradialytic Parenteral Nutrition—observational studies 
Cherry 
(2002) [55] 
Case series, 12 months 
n = 24. Dialysis  
(Stage 5, PD). 
Malnourished, using 
criteria 
Intervention: 2 formulations 
750 mL and 1000 mL IDPN, 
both 925 non protein calories, 
1000-mL formulation provided 
an extra 25 g of protein. 
Anthropometry (dry body weight). 
Biochemistry  
(serum albumin) 
Body weight increased from median 46.8 kg at baseline to 47.5 
at 6 months and 53.8 at 12 months (p < 0.05, p < 0.05, p < 
0.003 respectively). Serum albumin levels increased from 
median of 27.5 at baseline to 31.0 at 3 months (p < 0.05) and 
30.5 at 12 months in malnourished HD patients. Significant 
attrition at 9 and 12 months (n = 16) 
IV 
Intradialytic Parenteral Nutrition—observational studies 
Joannidis 
(2008) [56] 
Prospective cohort 
study with matched 
controls, 6 months 
n = 12. Dialysis  
(Stage 5, PD) with 
MICS. Controls had no 
malnutrition 
Intervention: IDPN 100 mL 
glucose 60%, 100 mL Elolipid 
20% (soya bean oil  
100 g/1000 mL, glycerol  
25 g/1000 mL, egglecithin  
12 g/1000 mL  
Control: usual dialysis 
Anthropometry (weight, BMI) 
Biochemistry (lipids, inflammatory 
markers 
Mean body weight increased from 61.7 ± 7.7 to 63.9 ± 8.9 
kg (p = 0.03) and BMI increasred from 21.9 ± 3.4 to 22.8 ± 
3.9 kg/m2, p = 0.03, compared to no change in control 
group. nPCR values differed significantly between patients 
at baseline but no significant difference was observed at 
the completion of the study for any other biochemical or 
nutritional markers. 
III-2 
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Korzets 
(2008) [57] 
Prospective 
observational case 
series, 1.5 to 17 months 
n = 22. Dialysis  
(Stage 5, HD) 
IDPN: Total E 1174–1677 kcal; 
Amino acids 10% 50–85 g; 
dextrose 50% 125–185 g; 
Clinoleic 20% 50–70 g, 
following major surgical or 
medical illnesses 
Anthropometry. Biochemistry 
(protein catabolic rate, 
albumin, pre-albumin, 
creatinine) .Dialysis adequacy 
nPCR increased from 0.7 ± 0.2 to 1.2 ± 0.2g protein/kg/ day (p < 
0.0001); serum albumin increased from 28± 5 g/L to 38 ± 2 g/L (p < 
0.0001); serum pre-albumin levels increased from 210 ± 82 to 300 ± 
52 mg/L (p < 0.01 and serum creatinine increased from 504 ± 195 to 
672 ± 186 μmol/L (p = 0.016). Serum cholesterol increased from 3.5 ± 
1.4 to 4.4 ± 1.4 mmol/L (p < 0.0001). Kt/V levels and weight did not 
change significantly during IDPN (1.43 ± 0.22 to 1.46 ± 0.26). 
IV 
Percutaneous Endoscopic Gastrostomy (PEG) feeding 
(Sayce 
2000) [58] 
Case series. Pre and 
post intervention over 
3 months 
n = 8. Dialysis (Stage 5, 
HD). +  malnutrition 
Various PEG feeding regimens; 
E 1983–7205 kcal/day;  
Pro 17–61 g/day 
Anthropometry (weight, skin 
folds). Biochemistry (albumin). 
Cost (hospitalisations and 
complications) 
Median dry weight increased from 43 to 48.3 kg (p = 0.012); BMI 
increased from 16.4 to 18.8 kg/m2 (p = 0.012); MUAC ↑ from 20.2 to  
24.8 cm (p = 0.018); TSF increased from 7.3 to 11.3 mm (p = 0.046); 
MUAMC increased from 17.7 to 19.8 cm (p = 0.027); Serum albumin 
increased from 29.5 to 36.5 g/L (p = 0.011) 
IV 
* CKD Chronic Kidney Disease; * HD Haemodialysis; * PD Peritoneal Dialysis; * GFR Glomerular Filtration Rate; * RCT Randomised Controlled Trial; * MPD Moderate protein diet; * LPD Low protein diet; * VLPD Very low protein diet;  
* KA Keto-acids; * NHF National Heart Foundation; * LSD Low sodium diet; * HSD High sodium diet, * BUN Blood urea nitrogen; * QOL quality of life; * POM profile of mood states; * BSA body surface area; * iPTH intact parathyroid 
hormone; * AAPD Amino acid peritoneal dialysate; * LBM Lean body mass; * WBPT Whole body protein turnover; * IDPN Intra-dialytic parenteral nutrition; *MICS malnutrition-inflammation complex syndrome; * WBPT Whole body 
protein synthesis; * UAER Urinary Albumin Excretion Rate; * PCR Protein Catabolic Rate; * nNPA Normalised Protein Appearance; * CRP c-reactive protein; * SGA Subjective Global Assessment; * PG-SGA Patient Generated Subjective 
Global Assessment; * Hb Haemoglobin; * HDL High density lipoprotein; * LDL low density lipoprotein; * VLDL very low density lipoprotein, TG Triglyceride; * PO4 phosphate; * HCT hydrochlorothiazide; * MUAC Mid Upper Arm 
Circumference; * TSF Triceps Skinfold Thickness; * MUAMC Mid Upper Arm Muscle Circumference; * MAMC Mid Arm Muscle Circumference; * BMI Body mass index; * EPA Eicosopentanoic Acid; * DHA Decosahexanoic Acid;  
* Ca Calcium; * ONS Oral Nutrition Support; * CV Cadiovascular; * KDQoL Kidney Disease Quality of Life; * CI Confidence Interval; * Na sodium; * LV left ventricular; *ESRD End Stage Renal Disease; *IQR interquartile range.  
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Table 3. Nutritional Parameter in International Guidelines with evidence. 
Nutrient or 
Requirement 
Most Current Equivalent Guideline Statement 
Grade of Evidence 
Equivalent to 
GRADE [62] 
Energy-dialysis 
KDOQI (2000) [60], BDA (2013) [19] 
The recommended daily energy intake for maintenance haemodialysis or chronic peritoneal dialysis patients is  
35 kcal/kg ideal body weight/day (146 kJ/kg IBW/day) for those who are less than 60 years of age and 30 to  
35 kcal/kg body weight/day (126–146 kJ/kg IBW/day) for individuals 60 years or older. 
C 
Protein–pre-dialysis 
CARI (2013) [15] 
We recommend for patients with early CKD consume a normal protein diet of 0.75–1.0 g/kg IBW/day with 
adequate energy. This is the Recommended Dietary Intake for the general population. 
1C 
A low protein diet (≤0.6 g/kg IBW/day) to slow down CKD progression is not recommended because of the risk 
of malnutrition. 
1C 
We suggest that patients with excess protein intakes reduce their intakes to the RDI levels as a high protein diet 
may accelerate renal function decline in mild renal insufficiency 
2C 
Protein–pre-dialysis 
with keto acids 
ADA (2010) [18] 
For adults with CKD without diabetes, not on dialysis, with an eGFR < 20 mL/min, a very low protein controlled 
diet providing 0.3 g–0.5 g dietary protein per kg of body weight per day with addition of keto acid analogs to meet 
protein requirements may be recommended. International studies report that additional keto acid analogs and 
vitamin or mineral supplementation are needed to maintain adequate nutrition status for patients with CKD who 
consume a very low protein controlled diet (0.3–0.5 g/kg/day) 
Strong, conditional 
evidence 
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Protein-dialysis 
KDOQI (2000) [59] BDA (2013) [19] 
The recommended dietary protein intake for clinically and weight stable maintenance HD patients is 1.1 g/kg ideal body 
weight/day. At least 50% of the dietary protein should be of high biological value. For clinically and weight stable PD 
patients, the recommended protein intake is 1.0-1.2 g/kg ideal body weight/day. Those who are not stable may need 
higher levels of protein. 
C 
Sodium-pre-dialysis 
CARI (2013) [15] 
We recommend that early CKD patients restrict their dietary sodium intake to below 100 mmoL per day or less, as it 
reduces blood pressure and albuminuria in patients with CKD. 
1C 
Sodium-dialysis 
KDOQI (2000)[59]  
Dietary sodium intake of less than 2.4 g/day (less than 100 mmol/day) should be recommended in most adults with 
CKD and hypertension. 
A 
Fluid-pre-dialysis 
CARI (2013) [15] 
We suggest that patients drink fluids in moderation. For most patients with early CKD, a daily fluid intake of 2–2.5 L 
(including fluid content of foods) is sufficient, although this may need to be varied for individual circumstances. 
2C 
Phosphate-pre-dialysis 
CARI (2013) [15] 
We suggest that early CKD patients (stages 1–3) should not restrict dietary phosphate intake as restrictions of dietary 
phosphate does not influence renal or cardiovascular outcomes in these patients. 
2C 
 
KDIGO (2009) [17] 
In patients with CKD stages 3–5, we suggest maintaining serum phosphorus in the normal range. 2C 
In patients with CKD stages 3–5 we suggest using phosphate-binding agents in the treatment. of hyperphosphatemia. 2D 
It is reasonable that the choice of phosphate binder takes into account CKD stage, presence of other components of 
CKD–MBD, concomitant therapies, and side-effect profile. 
Not graded 
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Phosphate-dialysis 
KDIGO (2009) [17] 
In patients with CKD stage 5D, we suggest lowering elevated phosphorus levels toward the normal range. 2C 
In patients with CKD stages 5D we suggest using phosphate-binding agents in the treatment. of 
hyperphosphatemia. 
2B 
It is reasonable that the choice of phosphate binder takes into account CKD stage, presence of other 
components of CKD–MBD, concomitant therapies, and side-effect profile. 
Not graded 
In patients with CKD stages 3–5D and hyperphosphatemia, we recommend restricting the dose of  
calcium-based phosphate binders and/or the dose of calcitriol or vitamin D analog in the presence of persistent 
or recurrent hypercalcemia. 
1B 
In patients with CKD stages 3–5D and hyperphosphatemia, we suggest restricting the dose of calcium based 
phosphate binders in the presence of arterial calcification and/or adynamic bone disease and/or if serum PTH 
levels are persistently low. 
2C 
In patients with CKD stages 3–5D, we recommend avoiding the long-term use of aluminum-containing 
phosphate binders and, in patients with CKD stage 5D, avoiding dialysate aluminum contamination to prevent 
aluminum intoxication. 
1C 
In patients with CKD stages 3–5D, we suggest limiting dietary phosphate intake in the treatment of 
hyperphosphatemia alone or in combination with other treatments. 
2D 
Fibre 
CARI (2103) [15] 
We suggest patients with early CKD consume a diet rich in dietary fibre that is associated with reduced 
inflammation and mortality in CKD patients. 
2D 
Potassium-pre-dialysis 
CARI (2013) [15] 
We suggest that early CKD patients with persistent hyperkalaemia restrict their dietary potassium intake with 
the assistance of a qualified dietitian. 
2D 
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Vitamin D-pre-dialysis 
CARI (2013) [15] 
We suggest Vitamin D deficiency (25 hydroxy vitamin D < 37.5nmol/L) and insufficiency (25 hydroxy 
vitamin D 35.5–75 nmol/L) if present be corrected using treatment strategies for the general population:  2C 
• Daily oral intake 19–50 year: 5 μg; 51–70 year: 10 μg; >70 year: 15 μg (1 μg = 40 IU). It is very difficult 
to meet RDI with food intake alone. 2D 
• A few minutes in Australian summer for fair skinned people and 2–3 h of sunlight/week in winter in 
southern regions. 2D 
We recommend a prescription of vitamin D therapy for early CKD patients with secondary 
hyperparathyroidism, as it has been shown to be effective in suppressing elevated levels of parathryroid 
(PTH) hormone. There is insufficient evidence to determine whether this improves patient-level outcomes 
and the potential benefits of vitamin D therapy must be weighed against its potential deleterious effects, 
including hypercalcaemia, hyperphosphataemia, vascular calcification, adynamic bone disease and 
accelerated progression of CKD. 
1A 
We recommend that early CKD patients on vitamin D therapy have their calcium, phosphate, PTH, alkaline 
phosphate and 25(OH) vitamin D level monitored regularly. 1C 
Vitamin D-dialysis 
KDIGO (2009) [17] 
In patients with CKD stage 5D and elevated or rising PTH, we suggest calcitriol, or vitamin D analogs, or 
calcimimetics, or a combination of calcimimetics and calcitriol or vitamin D analogs be used to lower PTH. 2B 
Calorie  
restriction/weight loss 
CARI (2013) [15] 
We recommend that overweight/obese patients with CKD should be prescribed caloric restriction under the 
management of an appropriately qualified dietitian. A reduction in weight can mean an improvement of CKD. 
1C 
We suggest, in the absence of specific recommendations for CKD, overweight and obese patients are 
encouraged to aim for a body mass index (BMI) of between 18.5–24.9 kg/m2 and waist circumference of 
≤102 cm for men and ≤88 cm for women. 
2C 
CMA (2008) [11] 
Obese (BMI > 30.0 kg/m2) and overweight (BMI 25.0–29.9 kg/m2) people should be encouraged to reduce 
their BMI to lower their risk of chronic kidney diseaseand end-stage renal disease. D 
Maintenance of a health body weight (BMI 18.5–24.9 kg/m2; waistcircumference < 102 cm for men,  
<88 cm for women) is recommended to prevent hypertension. C 
Or to reduce blood pressure in those with hypertension. B 
All overweight people with hypertension should be advised to lose weight. B 
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Other dietary 
components 
CARI (2013) [15] 
Fruit and vegetables—we suggest adults with early CKD consume a balanced diet rich in fruit and vegetables, 
as these appear to reduce blood pressure and have renoprotective effects comparable to sodium bicarbonate. 
2C 
Mediterranean diet—we suggest adults with CKD consume a Mediterranean style diet to reduce 
dyslipidemia and to protect against lipid peroxidation and inflammation. 
2C 
Counselling 
CARI (2013) [15] 
We suggest that patients with progressive CKD have individualised dietary interventions involving an 
appropriately qualified dietitian. 
 
NICE (2008) [13] 
Where the clinician in discussion with the patient has decided that dietary intervention to influence 
progression of CKD is indicated, an appropriately trained professional should discuss the risks and benefits 
of dietary protein restriction, with particular reference to slowing down the progression of disease vs. 
protein-calorie malnutrition. 
2C 
Where dietary intervention is agreed this should occur within the context of education, detailed dietary 
assessment and supervision to ensure malnutrition is prevented. 
Not graded 
Offer dietary advice to people with progressive CKD concerning potassium, phosphate, protein, calorie and 
salt intake when indicated. 
Conservative 
management 
CMA (2008) [11] 
Renal programs and care providers for patients with progressive chronic kidney disease who choose not to 
pursue renal replacement therapies should ensure patients have access to an interdisciplinary team to provide 
comprehensive conservative management. 
• All chronic kidney disease programs and care providers should have a mechanism by which to develop 
documents and processes for advanced-care planning. 
• Comprehensive conservative management protocols should include symptom management, psychological 
care and spiritual care. 
• Coordinated end-of-life care should be available to patients and families. 
Not graded 
 22 
 
The Australian CARI guidelines, shown in Table 3, state that a protein-controlled diet consisting of 
0.75–1.0 g/kg/day, is recommended for adults pre-dialysis (Stages 3–4) [15]. The administration of a 
low protein diet (<0.6 g/kg/day) to slow renal failure progression is not justified when the reported 
clinically modest benefit on glomerular filtration rate decline is weighed against the concomitant 
significant declines in clinical and biochemical parameters of nutrition [15]. It is the most recent of the 
international guidelines assessing this question and is at odds with the systematic reviews [22,23]. 
The British Dietetic Association’s guidelines on protein intake in both haemodialysis (HD) and 
peritoneal dialysis (PD) recommend a lower level of protein intake than previous guidelines at 1.1 g/kg 
ideal body weight/day for those undergoing maintenance haemodialysis and 1.0–1.2 g/kg ideal body 
weight/day for those on maintenance peritoneal dialysis [19]. These recommendations are graded C 
using the Scottish Intercollegiate Guideline Network criteria, that is based on well-conducted cohort or 
case control studies with a low risk of confounding and a moderate probability that the relationship  
is causal [12]. The authors emphasise the importance of adequate energy (126–167 kJ/day in HD  
and 146 kJ/day for PD in adults under 60 years and 126–146 kJ/day for those over 60 years). This 
recommendation is slightly lower than previously recommended and is based on medically well 
patients with stable body weights and the authors caution when applying these recommendations to 
less well patients [19]. 
The guidelines on vitamin D (Table 3) focus on the general population decline in serum 25 hydroxy 
vitamin D and methods to address this in early CKD (Stages 1–4) [15]. In later stages of disease, 
recent guidelines focus on the combined effects of calcium, phosphate, parathyroid hormone (PTH) 
and vitamin D on outcome [14,17]. The cohort study by Wang et al. aimed to explore the relationship 
between serum 25(OH)-hydroxy vitamin D (25(OH)D) in PD patients and long term clinical  
outcomes [36]. They found that 87% of the cohort were deficient or insufficient in 25(OH)D  
(i.e., <75 nmol/L) and that lower serum 25(OH)D levels were associated with an increased risk of 
cardiovascular events but not long term mortality [36]. The effects of oral paricalcitol supplementation 
on biochemical markers (including proteinuria) have been studied in both pre-dialysis and early CKD 
patients (Stages 1–4). A small, six month randomized controlled trial (RCT) found a modest effect size 
of oral paricalcitol supplementation of 1 μg/day vs. placebo, with the intervention group demonstrating 
a 17.6% decrease in spot urinary protein-creatinine ratio vs. a 2.9% increase for controls (p = 0.04) [34]. 
It was also noted in this study that serum iPTH fell significantly amongst those who received 
paricalcitol supplementation (p = 0.01) [34]. Agarwal et al. similarly found that oral paricalcitol 
supplementation (mean dose 9.5 μg/week) was significantly associated with 51% vs. 25% (p = 0.004) 
reduction in proteinuria in the intervention group compared to controls and 3.2 greater odds for a 
reduction in proteinuria independent of treatment for Renal Angiotensin Aldosterone blockade [35]. 
The KDIGO guidelines (see Table 3) recommend calcitriol or other vitamin therapy in those with 
elevated parathryroid hormone [17]. The CARI guidelines while recommending vitamin D therapy in 
early kidney disease for those with elevated PTH warn against the risk of vitamin D therapy in the face 
of elevated serum calcium and phosphate levels, which should be monitored regularly [15]. 
The evidence for the modification of fat in CKD to moderate cardiovascular outcomes is limited. 
Beavers et al. found that supplementation of 6 g omega-3 fatty acids had no effect on total 
homocysteine levels in HD patients over 6 months [37]. Saltissi et al. found that dietary compliance 
was a major issue [38]. A dialysis dietary prescription modified to meet the National Heart Foundation 
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guidelines of reduced intake of saturated fat and cholesterol, led to a significant reduction in total 
cholesterol and low density lipoprotein (LDL) cholesterol in HD patients with little effect in PD 
patients [38]. All guidelines published since 2006, recommend controlling salt intake below 100 mmol 
sodium/day (2.3 g sodium) as an important feature of managing hypertension [11,12,15,18], although 
not addressed at any particular stage of CKD. One randomized controlled double blind crossover study 
of 34 patients with proteinuria and without diabetes was located reporting the effect of a low sodium diet  
(50 mmol/day) being as efficacious as treatment with hydrocholorothiazide (an angiotensin receptor II 
antagonist) at reducing proteinuria and blood pressure when combined with a diuretic [39]. Sodium 
restriction itself exerted a modest, yet significant, antiproteinuric effect [37]. Actively restricting 
sodium to less than 100 mmol/day (5 g salt) in those undergoing haemodialysis resulted in less 
hypertensive medications used (7% vs. 42%), better ventricular function and less intradialytic 
hypotension compared to those whose blood pressure was controlled by medication [40]. Using 
sodium excretion as a surrogate for sodium intake, Boudville showed that excretions in the lowest 
tertile (114 mmol/day) resulted in significantly fewer hypertensive medications (2 vs. 2.7, p = 0.01) used 
in those with GFR < 30 mL/min, than those in the highest tertile (166.7 mmol/day). This effect was 
even more marked in those with GFR ≤ 15 mL/min [41]. 
The effect of dietary fibre supplements and a high fibre diet, on patient reported symptoms of 
constipation amongst a PD population, suggested that 6–12 g/day of partially hydrolysed guar gum 
added to usual intake was as effective as usual laxative treatment for preventing constipation in the 
majority of included PD patients and was associated with less unfavorable side effects [42]. Both 
Saltissi and Sutton studies were case series without control groups [38,42]. 
Compliance with diet prescription remains an issue. Twenty-eight per cent (28%) of participants 
under-reported protein intake in both a very low protein diet (VLPD) of 0.3 g/kg/day plus keto-acids 
(KA) diet to a level of 0.66 g/kg/day and a low protein diet (LPD) of 0.6 g/kg/day in pre-dialysis 
patients. While compliance was poor in both groups, the prescription of the VLPD + KA delivered 
improved biochemical markers, with significant improvements noted in serum urea nitrogen, serum 
bicarbonate and urinary phosphorous [31]. In 423 pre-dialysis patients (Stages 4 and 5) randomized  
to receive two different protein levels, LPD (0.55 g/kg/day) or a Moderate Protein Diet (MPD)  
of 0.8 g/kg/day, for 3 months with follow up to 48 months there were no differences between groups  
at 6 and 18 months, however there was greater compliance with the MPD [32]. In a case control study 
of Stage 3–5 CKD patients, Kanazawa demonstrated the compliant group, with dietary protein intakes 
maintained at 0.69 g/kg body weight/day, had smaller decline in GFR, however no measures of change 
in body composition were recorded and there was no difference in health-related quality of life [33]. 
In an open RCT in 28 PD patients, randomized to receive a powdered egg-albumin protein supplement 
(30 g/day providing 22 g protein) vs. nutrition counselling over six months resulted in significantly 
improved serum albumin (2.64 ± 0.35 vs. 3.05 ± 0.72 g/dL), energy intake (1331 ± 342 vs.  
1872 ± 698 kcal/day), protein intake (1.0 ± 0.3 vs. 1.7 ± 0.7 g/kg) and nPNA (1.00 ± 0.23 vs. 1.18 ± 
0.35 g/kg/day) amongst the intervention group when compared to baseline measures, and frequency of 
moderate-severe malnutrition decreased 28% in the intervention vs. 6% in the control group [45]. 
Interestingly, compliance in this study was reported as 90%. 
Teixido-Planas et al. conducted a 12 month open RCT of 65 PD participants, comparing daily 
consumption of 200 mL 1.0 kcal/mL liquid oral nutrition support (ONS), in addition to usual dietary 
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intake, against those who consumed only their usual dietary intake [43]. Based on an “intention to 
treat” analysis, only an improvement in total lymphocyte count (p = 0.0066) between intervention and 
controls reached significance. The supplement was not found to be suitable for long term use due to 
non-compliance with 31% of the intervention group dropping out. A similar study by Caglar et al. with 
ONS showed improvements in albumin, pre-albumin and SGA [44], however the compliance rate 
(32%) was similar, with a 46% dropout rate. 
Five studies investigating the effect of structured dietetic counseling on compliance with dietary 
prescriptions have shown differing results. Campbell et al. randomized 56 pre-dialysis patients  
(Stages 4 and 5) to fortnightly, individualized counseling on a prescription of 0.75 g/kg/day protein  
and 145 kJ/kg/day energy vs. written education material for 3 months [46]. The intervention group had 
a significantly lower reduction in body cell mass and improvement of 17.7 kJ/kg/day energy intake and 
subjective global assessment (SGA). Improvements in nutritional status in the intervention group 
translated to significant improvements in the symptoms, cognitive functioning and vitality subscales in 
the Kidney Disease Quality of Life tool, KDQoL [47]. Sullivan also showed in 279 HD patients in a 
cluster RCT for 3 months that counseling on reducing phosphates in foods compared to usual care 
significantly reduced serum phosphate levels by 0.6 mg/dL, largely through improvements in food 
label reading [48]. Conversely, Morey in 67 HD patients randomized to monthly vs. 6 monthly counseling 
was unable to maintain a reduction in serum phosphate of 0.25 mg/dL at 3 months, at the 6 month 
follow-up [49]. A retrospective cohort study over 2 years of 65 HD patients receiving a 6 monthly 
dietetic review with intensive follow-up for nutrition parameters falling below recommended levels, 
showed a significant reduction in malnutrition (SGA-B reducing from 14% to 3%), maintained serum 
albumin, potassium an dry weight and significant reduction in serum phosphate [50].  
The evidence for the effect of nutrients in peritoneal dialysis solution is limited to two small studies 
[51,52]. Improvements in overall protein balance improved in a randomized cross over study of 8 
patients over 14 days [51] and also in another study which was open labeled and not controlled in 16 
patients over 3 months [52]. The use of intradialytic parenteral nutrition (IDPN) solution in HD 
patients has also only been conducted in small studies, showing improvements in hepatic albumin 
synthesis and whole body fat free  
mass [53-57]. In the cross over study of 8 patients using both IDPN and oral supplements, the oral 
administration resulted in persistent anabolic benefits in the post dialysis phase, which was not seen 
with IDPN [55]. In a case series over 12 months of 24 malnourished PD patients, in which there was 
significant attrition >50%, the IDPN was associated with increased body weight and improved serum 
albumin levels [57]. A small case series in haemodialysis patients, using Percutaneous Endoscopic 
Gastrostomy feeding showed improvements in anthropometric measures over a 3 month period [58]. 
4. Discussion 
The focus of guidelines on nutrition and CKD published since 2006 has been on early prevention 
and lifestyle modification required to prevent progression to ESRD [11,12,15] or the management of 
renal bone disease [17]. The KDOQI guidelines on nutrition have not been updated since 2000 [59]. 
Addressing general population’s sub-optimal serum vitamin D levels, as well as in early CKD is a 
priority. Other chronic diseases, such as obesity, diabetes and hypertension, which affect the population 
 25 
 
at large, require management to prevent progression to CKD [15]. The treatment of these diseases has 
a large nutrition component which needs to be recognized [6]. 
The approach for managing elevated serum phosphate, through the use of phosphate binders as an 
adjunct to the restriction of dietary intake, has also been recognized. The KDIGO guidelines continue 
to recommend restricting dietary phosphate in combination with other treatments, however the evidence 
is poor [5]. The CARI guidelines state clearly that restriction of diet runs the risk of precipitating 
malnutrition and thus has promoted moderate restrictions in protein, phosphate and sodium in the  
pre-dialysis period to levels commensurate with the general population [15]. The studies, specifically 
looking at dietitian led control of phosphate intake, showed promise but further studies need to be 
conducted on the frequency of dietetic counseling to ensure long term impact on dietary control [49,50]. 
Issues of compliance with restricted diets remains a weakness in many of the studies reported here 
and those promoting regular contact with a dietitian mostly report improved outcomes. The previous 
DAA guidelines [7] have had wide currency with dietitians in Australia and New Zealand and are 
largely still relevant in the present day. These guidelines used the Nutrition Care Process (NCP) to 
guide the development of clinical questions. The NCP consists of nutrition assessment, diagnosis, 
intervention and monitoring and evaluation [8] and is outcome driven in that nutritional parameters 
collected as part of the nutrition assessment and addressed through the nutrition prescription, are then 
re-assessed or evaluated to establish the impact of the nutrition intervention. These outcomes commonly 
include intermediate outcomes, such as nutrient intake, anthropometric measures and biochemical markers. 
Studies on the effect of nutrition prescription on clinical outcomes, such as mortality, hospitalization or 
cost are limited. While the NCP is useful for practical purposes, grading of evidence in line with 
international recommendations on harmonizing guidelines is still required [21]. One advantage of 
these nutrition guidelines is the rigorous independent review process undertaken using the Appraisal of 
Guidelines for Research and Evaluation (AGREE) tool, which has been recommended for future 
evaluation of guidelines [60]. Areas requiring most revision for the future include recommendations on 
vitamin D and phosphate. Further studies on the effect of intradialytic parenteral nutrition and enteral 
support on dialysis are also warranted. 
5. Conclusions 
Overall, the body of evidence supporting nutritional interventions for improving patient outcomes 
in CKD is primarily based on low level evidence or isolated randomized clinical trials. Much of the 
evidence around dietary prescription relies on retrospective and uncontrolled cohort studies and the 
quality of the body of evidence is poor. Most outcomes assessed are generally biochemical endpoints, 
such as change in serum levels, rather than clinical ones, such as mortality, hospitalization, cost and 
patient quality of life. There is general agreement across guideline recommendations for the levels of 
protein in early CKD and on dialysis; however, guidance on the use of very low protein diets with  
keto-analogues in conservative treatment of those with GFR < 15 mL/min is warranted. While the 
evidence from a few observational trials suggests that these diets pose no greater risk on mortality than 
dialysis as treatment, better controlled trials are required to confirm this. Further research on the 
optimal intakes of sodium, phosphate, fats and fibre in well controlled studies are required, as are 
studies into micronutrients and other components such as antioxidants. Studies on sun exposure 
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combined with diet are required to determine optimal vitamin D status. The collaborative effort to use 
a global approach to international guidance in management of chronic kidney disease is welcome. 
While more evidence based studies are warranted, the customary nutrition prescription remains 
satisfactory with the exception of Vitamin D and phosphate. In these two areas, additional research is 
urgently needed, given the potential of adverse outcomes for the CKD patient. The role of nutrition in 
the management of CKD is important and needs to be included in further promotion of research 
outcomes and future guidelines. 
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Appendix 1. Grading of evidence for different guidelines. 
Grading Body Best evidence (A/1A/Strong) Good Evidence (B/Fair) Mixed Evidence (C) Weak Evidence (D) 
 A—Excellent B—Good C—Satisfactory D—Poor 
NHMRC. National 
Health and Medical 
Research Council, 
Australia (2009) [20] 
Body of evidence can be trusted to guide 
practice. Several level I or II studies with low 
risk of bias; Excellent consistency across 
studies; Very large clinical impact; Results 
are directly generalisable to target population; 
Results are directly applicable to the 
Australian healthcare context. 
Body of evidence can be trusted to guide 
practice in most situations. One or two level II 
studies with low risk of bias or systematic 
review of multiple level III studies with low 
risk of bias. Most studies are consistent and 
inconsistencies can be explained. Substantial 
clinical impact; Results are directly 
generalisable to target population with some 
caveats; Results are directly applicable to the 
Australian healthcare context with few caveats. 
Body of evidence provides some support for 
recommendation(s) but care should be taken in its 
application. Satisfactory level III studies with low 
risk of bias or level I or II studies with moderate 
risk of bias. Some inconsistency reflecting genuine 
uncertainty around question. Moderate clinical 
impact; Not directly generalisable to target 
population but could be sensibly applied. Results 
are probably applicable to the Australian healthcare 
context with some caveats. 
Body of evidence is weak and 
recommendation must be applied with 
caution. Level IV studies or level I to III 
studies with high risk of bias. Evidence is 
inconsistent; Slight or restricted clinical 
impact. Not directly generalisable to target 
population hard to judge whether it is 
sensible to apply. Results are not 
applicable to the Australian healthcare 
context. 
SIGN Scottish 
Intercol-legiate 
Guidelines Network 
2008 [12] 
A B C D 
Good Practice 
Points 
At least one meta-analysis, systematic 
review, or RCT rated as 1++, and directly 
applicable to the target population; OA body 
of evidence consisting principally of studies 
rated as 1+, directly applicable to the target 
population, and demonstrating overall 
consistency of results. 
A body of evidence including studies rated as 
2++, directly applicable to the target 
population, and demonstrating overall 
consistency of results; OR; Extrapolated 
evidence from studies rated as 1++ or 1+. 
A body of evidence including studies rated as 2+, 
directly applicable to the target population, and 
demonstrating overall consistency of results; OR; 
Extrapolated evidence from studies rated as 2++. 
Evidence level 3 or 
4; Extrapolated 
evidence from 
studies rated  
as 2+. 
Recommended 
best practice based 
on the clinical 
experience of the 
guidelines 
development 
group. 
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Canadian Society 
Nephrology (2008) [11] 
High quality RCT or meta-analyses with 
adequate power and clinically important 
outcomes 
High quality RCT or meta-analyses with 
adequate power but outcome is a validated 
surrogate or results need to be extrapolated 
from study population to real population 
OR; High quality RCT or meta-analyses 
with inadequate power but with clinically 
important or validated surrogate outcome 
High quality RCT or meta-
analyses with adequate power 
but outcome is neither clinically 
important or a validated surrogate 
outcome OR; Observational 
study with statistically 
significant results and outcome 
is clinically important or a 
validated surrogate AND study 
population is representative of 
population recommendation is 
for OR results can be 
extrapolated from study 
population to  
real population. 
High quality RCT or meta-analyses with inadequate power and 
neither clinically important nor validated surrogate outcomes OR; 
Observational study with statistically significant results but neither 
clinically important nor validated surrogate outcome OR; 
Observational study with inadequate power and applicability of the 
study is irrelevant. 
KDIGO 
Kidney Disease 
Improving Global 
Outcomes (2013)[5]  
A High B Moderate C Low D Very Low 
We are confident that the true effect lies 
close to that of the estimate of the effect. 
Level 1 “We recommend” 
Most people in situation would want the 
recommended course of action and only a 
small proportion would not. The 
recommendation can be evaluated as a 
candidate for developing a policy or a 
performance measure. 
The true effect is likely to be close to the 
estimate of the effect, but there is a 
possibility that it is substantially different. 
Level 2 “We suggest”; The majority of 
people in situation would want the 
recommended course of action, but many 
would not. The recommendation is likely to 
require substantial debate and involvement 
of stakeholders before policy can be 
determined. 
The true effect may be 
substantially different from the 
estimate of the effect. 
The estimate of effect is very uncertain, and often will be far from 
the truth. 
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 A B  C 
KDOQI. National 
Kidney Foundation 
-Kidney Disease 
Outcome Quality 
Initiative (2002) 
[61] 
It is strongly recommended that clinicians 
routinely follow the guidelines for eligible 
patients. There is strong evidence that the 
practice improves health outcomes. 
It is recommended that clinicians 
routinely follow the guideline for eligible 
patients. There is moderately strong 
evidence that the practice improves 
health outcomes 
 
It is recommended that clinicians consider following the clinical 
practice recommendation for eligible patients. This recommendation 
is based on either weak evidence or on the opinions of the work 
group and reviewers that the practice might improve health outcomes. 
 Strong  Fair Weak Consensus 
ADA. American 
Dietetic 
Association (2010) 
[18] 
The workgroup believes the benefits of the 
recommended approach clearly exceed the 
harms (or that harms clearly exceed 
benefits in the case of a strong negative 
recommendation) and that the quality of the 
supporting evidence is excellent/good  
(grad I or II). 
 
The workgroup believes the benefits 
exceed the harms (or that harms clearly 
exceed benefits in the case of a strong 
negative recommendation) but the 
quality of evidence is not as strong 
(grade II or III) 
Quality of evidence that exists is 
suspect or well done studies 
(grade I, II or III) show little 
clear advantage to one approach 
versus another. Patient 
preferences should have a 
substantial influencing role in 
patient care. 
A consensus recommendation 
means that expert opinion (grade 
IV) supports the guideline 
recommendation even though the 
available scientific evidence did 
not present consistent results, or 
controlled trials were lacking. 
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CARI Caring for  1A 2A 1B 2B 1C 1D 1D 2D 
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Australians with 
Renal Impairment 
(2013) [15] 
Strong 
recommendation 
High quality 
evidence. 
Consistent evidence 
from well 
performed RCTs or 
overwhelming 
evidence of some 
other form. Further 
research is unlikely 
to change our 
confidence in the 
estimate of benefit 
and risk. Strong  
recommendations 
can apply to most 
patients in most 
circumstances 
without reservation. 
Weak 
recommendation 
High quality 
evidence. 
Consistent evidence 
from well 
performed RCTs or 
overwhelming 
evidence of some 
other form. Further 
research is unlikely 
to change our 
confidence in the 
estimate of benefit 
and risk. Clinicians 
should follow a 
strong 
recommendation 
unless there is a 
clear rationale for 
an alternative 
approach. 
Strong 
recommendation. 
Moderate quality 
evidence. Evidence 
from RCTs with 
important 
limitations 
(inconsistent 
results, methods 
flaws, indirect or 
imprecise), or very 
strong evidence of 
some other research 
design. Further 
research may 
impact on our 
confidence in the 
estimate of benefit 
and risk. Strong 
recommendation 
and applies to most 
patients. 
Weak 
recommendation. 
Moderate quality 
evidence. 
Evidence from 
RCTs with 
important 
limitations 
(inconsistent 
results, methods 
flaws, indirect or 
imprecise), or 
strong evidence 
of some other 
research design. 
Further research 
may change the 
estimate of 
benefit and risk. 
Clinicians should 
follow a strong 
recommendation 
unless a clear and 
compelling 
rationale for an 
alternative 
approach is 
present. 
Strong 
recommendation. 
Low quality 
evidence. 
Evidence from 
observational 
studies, 
unsystematic 
clinical 
experience, or 
from RCTs with 
serious flaws. Any 
estimate of effect 
is uncertain. 
Strong 
recommendation, 
and applies to 
most patients. 
Some of the 
evidence base 
supporting the 
recommendation 
is, however, of 
low quality. 
Weak 
recommendation. 
Low quality 
evidence. 
Evidence from 
observational 
studies, 
unsystematic 
clinical 
experience, or 
from RCTs with 
serious flaws. Any 
estimate of effect 
is uncertain. 
Strong  
recommendation. Very low 
quality evidence; Evidence 
limited to case studies. Strong  
recommendation based mainly 
on case studies and expert 
judgement. 
Weak  
recommendation. Very low 
quality evidence 
Evidence limited to case studies 
and expert judgement 
Very weak  
recommendation, other 
alternatives may be equally 
reasonable. 
Appendix 1. Cont. 
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Grading of  
Recommendations 
Assessment 
Development 
Evaluation 
(GRADE) [62] 
High Moderate Low Very low 
We are very confident that the true effect 
lies close to that of the estimate of the 
effect. Further research is very unlikely to 
change our confidence in the estimate  
of effect. 
We are moderately confident in the effect 
estimate: The true effect is likely to be 
close to the estimate of the effect, but 
there is a possibility that it is 
substantially different. Further research 
is likely to have an important impact on 
our confidence in the estimate of effect 
and may change the estimate. 
Our confidence in the effect estimate is 
limited: The true effect may be 
substantially different from the estimate 
of the effect. Further research is very 
likely to have an important impact on our 
confidence in the estimate of effect and is 
likely to change the estimate. 
We have very little confidence in the effect estimate: The true effect 
is likely to be substantially different from the estimate of effect. Any 
estimate of effect is very uncertain. 
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